Fig. 7
From: JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers
Mean change from baseline in FVC over time in idiopathic pulmonary fibrosis patients treated with CC-930. a FVC percent predicted and b FVC in milliliters. a Defined as the last measurement on or before the day of the first dose of study drug. b 4 weeks post-treatment visit. The follow-up visit appears as a separate study week in the figure, with a dotted line connecting the last visit where subjects’ received drug to the follow-up visit. c Relative to the day of the first dose of study drug